For instance, in models of Alzheimer’s disease and Parkinson’s disease, C/EBPβ knockdown has been shown to reduce pathological markers and improve cognitive function (133–136). This evidence concerns the gene CEBPB and early-onset autosomal dominant Alzheimer disease.